Radiopharmaceutical Logistics Market Size, Share, Trends and Analysis Report, 2026-2035

Radiopharmaceutical Logistics Market is Projected to Reach USD 3.13 Billion by 2035

The global radiopharmaceutical logistics market, valued at USD 0.99 billion in 2025, is projected to reach USD 1.10 billion in 2026 and USD 3.13 billion by 2035, representing a CAGR of 12.31% during the forecast period 2026 to 2035. Market growth is expected to be supported by the expanding commercialization of diagnostic and therapeutic radiopharmaceuticals, increasing nuclear-medicine and treatment-site capacity, greater reliance on specialist outsourced logistics providers, and rising requirements for compliant handling, documentation and distribution across regulated supply chains.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

• Market Share by Type of Service: Currently, transportation and courier services account for the largest market share, while regulatory, customs and documentation services are expected to grow at the fastest rate.
• Market Share by Type of Radiopharmaceutical: Diagnostic radiopharmaceuticals lead the market in the current year, while therapeutic radiopharmaceuticals are projected to record the highest CAGR.
• Market Share by Radioisotope Half-Life: Currently, short half-life products represent the largest segment, while medium / long half-life products are anticipated to expand the fastest during the forecast period.
• Market Share by Temperature Range: Ambient / controlled room temperature logistics hold the largest share in current year, while ultra-low temperature / cryogenic logistics are expected to grow most rapidly through 2035.
• Market Share by End User: Currently, pharmaceutical and biotechnology companies constitute the largest customer group, while CDMOs and CMOs are expected to record the fastest growth during the forecast period.
• Market Share by Mode of Transportation: Within transportation and courier services market segment, road transport leads in the current year, while air freight grows fastest to become the largest mode by 2035.
• Market Share by Delivery Type: Within transportation and courier services market segment, standard / scheduled transportation accounts for the largest share, while time-critical / just-in-time transportation is projected to expand most rapidly.
• Regional Outlook: Currently, North America leads the global market, while Asia-Pacific is expected to record the fastest growth during the forecast period between 2026 and 2035.

Market Overview

Radiopharmaceutical logistics involves the controlled movement and handling of medical radiopharmaceuticals and isotopes under unusually narrow time, safety and product-integrity constraints. Radioactive decay limits the usable life of many products, while Class 7 transport requirements, validated temperature conditions, secure chain of custody and scheduled administration windows place additional demands on packaging, documentation, routing and delivery execution.

Recurring diagnostic radiopharmaceutical distribution remains a well-established part of nuclear-medicine supply chains, supported by radiopharmacies, imaging centers and routine dose-delivery networks. At the same time, the commercial expansion of therapeutic radiopharmaceuticals is introducing more complex logistics requirements. Patient-specific preparation, repeat treatment cycles, fixed administration schedules and cross-border movement require closer alignment between manufacturing release, shipment timing, specialized handling, condition monitoring and final delivery to treatment sites.

Radiopharmaceutical logistics is therefore progressing beyond the physical transportation of radioactive products towards coordinated management of the entire delivery process. Production timing, regulatory release, route planning, shipment condition and treatment-site readiness must be aligned within narrow operating windows. This growing need for synchronization is increasing the importance of real-time visibility, exception management and specialist handling in maintaining dose integrity and reliable treatment delivery.

Executive Market Insights

Radiopharmaceutical Logistics Market Ecosystem

The radiopharmaceutical logistics ecosystem brings together specialist logistics providers, integrated healthcare-logistics groups, radiopharmacy networks and manufacturer-led distribution systems. World Courier and Marken support multi-client transportation, regulatory coordination and shipment intervention, while Cardinal Health and Jubilant Radiopharma combine dose preparation with scheduled clinical delivery. Siemens Healthineers Radiopharma, Curium and Telix / RLS integrate manufacturing or dispensing with regional distribution infrastructure. These participants compete across transportation, monitoring and distribution services, but also collaborate when manufacturers require external air, ground, customs or last-mile support beyond their own networks. Further, investment in production sites, radiopharmacy capacity and precision-logistics technology are broadening geographic coverage and strengthening service integration across this specialized market.

The matrix below shows how leading radiopharmaceutical 3PL providers differ in their delivery infrastructure, radiopharmaceutical portfolios, compliance capabilities and geographic reach.

Leading Radiopharmaceutical Logistics Companies: Services Portfolio Snapshot

Market Trends Shaping the Radiopharmaceutical Logistics Industry

Patient-Specific Radiopharmaceuticals are Increasing Demand for Treatment-Scheduled Logistics

Patient-specific therapeutic radiopharmaceuticals are shifting logistics from conventional shipment booking to treatment-linked service planning. Novartis states that individual radioligand-therapy doses are prepared for specific patients and require highly time-sensitive delivery, while Cardinal Health's central pharmacies prepare patient-specific doses for delivery to designated hospital departments. Logistics capacity must therefore be aligned with manufacturing release and administration windows, with service-level agreements defining cutoff times, hand-off responsibilities, escalation procedures and qualified backup routes. Clinical-site communication also becomes part of the delivery service because production delays, missed connections or late final-mile transfers can disrupt both dose usability and treatment schedules.

This shift is increasing the commercial value of providers that can manage the complete treatment-linked delivery sequence rather than physical transportation alone. Supplier evaluation is placing greater weight on reserved capacity, contingency execution, clinical-site coordination and reliable hand-offs, creating stronger differentiation for specialist and integrated networks supporting therapeutic programs.

Real-Time Monitoring is Strengthening Exception Management in Time-Critical Logistics

Real-time monitoring is progressing from shipment-status reporting towards active exception management. World Courier combines location and condition visibility with control-tower oversight and alternative-route planning, while Marken integrates AIRTECH monitoring with its control-tower operations to identify route deviations, temperature excursions and unexpected delays. The structural change lies in connecting shipment data with predefined action. Shared milestones can identify which participant must respond, activate escalation procedures and preserve an auditable record across manufacturers, couriers, radiopharmacies and treatment sites. Visibility does not eliminate transport, handling or regulatory risk, but it can reduce the time between detecting a deviation and initiating corrective action.

These capabilities are making intervention readiness an important basis for logistics-provider differentiation. Customers are moving beyond asking whether tracking is available and assessing whether the provider offers staffed oversight, clear accountability, regulatory expertise and viable contingency capacity. Monitoring and control-tower capabilities can consequently strengthen service value when they demonstrably protect chain of custody and treatment timelines.

Regional Manufacturing Expansion is Reshaping Radiopharmaceutical Distribution Networks

The expansion of regional production and radiopharmacy capacity is changing where logistics activity originates and how far finished doses must travel. Novartis has located radioligand-therapy manufacturing facilities near treatment markets and major transport infrastructure, while Curium's integration of Monrol expanded its PET footprint and added manufacturing and logistics infrastructure across Eastern Europe and the Middle East. Siemens Healthineers Radiopharma similarly operates a distributed network of cyclotron-equipped facilities designed to manufacture PET products nearer to imaging centres. These developments can reduce selected long-haul movements of short-lived finished doses, while increasing regional replenishment, precursor and isotope transfers, interfacility backup activity and tightly scheduled final-mile delivery from a larger number of nodes.

This redistribution is changing route economics and geographic partnership requirements rather than removing logistics demand. Networks with local licensed capacity, standardized quality controls and reliable backup coverage can support shorter delivery lanes while maintaining consistency across multiple production points. In addition, the outsourced opportunity is likely to follow new manufacturing and dispensing locations, increasing the importance of regional courier capacity and treatment-site connectivity.

Industry Experts on Radiopharmaceutical Logistics Market

The safe movement of radiopharmaceuticals depends on a consistent regulatory foundation that can be applied across road, air, rail and maritime transport. Following the publication of the revised transport regulations in March 2026, Hildegarde Vandenhove (Director of the IAEA Division of Radiation, Transport and Waste Safety) stated "The IAEA transport regulations provide the internationally recognized framework that enables radioactive material to be transported safely and efficiently across all modes of transport." This underscores the importance of harmonized safety requirements in enabling international radiopharmaceutical distribution. However, differences in national, modal and carrier-level implementation continue to make specialist documentation, package validation, route assessment and regulatory coordination central to reliable cross-border execution.

In addition, the radiopharmaceutical logistics market report includes transcripts of the following third-party discussions:

• President and Chief Executive Officer, Small Organization, US
• Chief Executive Officer and Co-founder, Mid-sized Organization, US
• Chief Executive Officer and Co-founder, Mid-sized Organization, US
• Founder and Chief Technology Officer, Mid-sized Organization, Belgium
• Chief Executive Officer, Mid-sized Organization, Japan
• Chief Executive Officer, Small Organization, US
• President and Co-founder, Small Organization, US
• Vice President of Cell Technology, Mid-sized Organization, Belgium
• Associate Director, Regulatory Affairs, Mid-sized Organization, US
• Team Leader, Research and Development, Mid-sized Organization, Germany

Segmentation Analysis of Global Radiopharmaceutical Logistics Market

Market Segments

Based on the research, we have segmented the radiopharmaceutical logistics market into various key segments, outlined below.

Market Share Insights

Regional Market Share: North America Holds the Largest Share, While Asia-Pacific is Projected to Grow Fastest Through 2035

North America accounts for 39.0% of the radiopharmaceutical logistics market in 2026, supported by an established nuclear-medicine base and dense production, radiopharmacy and treatment infrastructure. Cardinal Health operates 130 nuclear pharmacies and 30 PET manufacturing facilities across the US, supporting recurring dose preparation and distribution over a broad clinical footprint. Novartis is also adding radioligand-therapy capacity near major patient markets. Together, this combination of mature clinical demand, distributed preparation capacity and established specialist delivery networks sustains North America's current revenue leadership.

Asia-Pacific is projected to record the fastest growth as nuclear-medicine utilization and regional supply capability expand simultaneously across Japan, Australia and Southeast Asia. For instance, Telix opened its first Asia-Pacific cyclotron facility in Yokohama in November 2025 and added an integrated Melbourne facility in July 2026. Meanwhile, Cyclotek's network supplies more than 150,000 patient doses annually across Australia and New Zealand and is also extending collaboration into Singapore. Together, these expansions demonstrate how distribution coverage is developing alongside clinical access across the region. Further, as the network develops from a smaller base, demand is rising for qualified local transport, reliable interfacility movements and specialist partnerships able to connect expanding radiopharmaceutical infrastructure with geographically dispersed clinical sites.

Why Do Transportation and Courier Services Lead, While Regulatory, Customs and Documentation Services Record the Strongest Growth?

Transportation and courier services capture more than 40% of the current radiopharmaceutical logistics market, supported by their role across every shipment stage, from origin collection and principal line-haul to final delivery. The segment's leadership is reinforced by recurring diagnostic distribution, short product half-lives and treatment schedules that require frequent, precisely timed movements. Current specialist logistics models use same-day, next-flight-out and dedicated final-mile services to limit delays and preserve the diagnostic or therapeutic utility of the shipment. These requirements make transportation and courier services the largest segment of the radiopharmaceutical logistics process.

Regulatory, customs and documentation services are expected to grow at a faster rate as international radiopharmaceutical movements become more complex. Shipments must comply simultaneously with radioactive-material transport rules and pharmaceutical-quality requirements, while licensing, packaging, carrier acceptance and customs procedures can vary across countries and transport hubs. The updated IAEA transport framework and current industry practices highlight the need for pre-release regulatory checks, importer and exporter support, audit-ready documentation and secure chain-of-custody records. As cross-border therapeutic and isotope movements expand, these activities are progressing from embedded administrative tasks toward specialized services that directly influence route feasibility, shipment release and delivery reliability.

Market Share by Mode of Transportation: Road Transport Sustains Current Leadership, While Air Freight Is Projected to Lead by 2035

Road transport holds maximum share of transportation and courier services revenue in the current year, primarily because radiopharmaceutical distribution remains concentrated within local and regional delivery catchments. High-frequency movements between radiopharmacies, production facilities, hospitals and imaging centres are generally completed by road, particularly where multiple doses must be delivered across repeat clinical routes. Siemens Healthineers Radiopharma, for instance, distributes more than 2.1 million PET doses annually to over 3,000 imaging centres through its radiopharmacy network, illustrating the recurring regional shipment volumes that underpin ground transportation demand.

Air freight mode is poised to experience faster pace of growth during the forecast period, driven by the increasing movement of medical isotopes, precursors, manufacturing intermediates and finished radiopharmaceuticals between geographically separated production and treatment markets. In fact, World Courier's coordination of airlines, ground teams, radiopharmacies and hospitals across cross-border shipments demonstrates the central role of airline-haul in connecting these supply-chain stages. As international and long-distance movements form a larger share of shipment activity, the market is shifting towards integrated air-ground networks that combine Class 7 air capacity with compliant airport transfers and dependable collection and final delivery.

Market Share by Type of Delivery: Scheduled Transportation Dominates Current Revenue, While Time-Critical Services Gain Share Most Rapidly

Standard / scheduled transportation holds the maximum share of transportation and courier services market size in 2026, reflecting the large volume of radiopharmaceutical doses supplied through recurring, pre-planned radiopharmacy and diagnostic-dose distribution. Jubilant Radiopharma's US radiopharmacy business supplies diagnostic and therapeutic unit doses to nuclear-medicine departments serving nearly four million patients annually. This predictable workload allows shipment consolidation, vehicles, drivers and receiving windows to be planned across a regular service schedule. Such route density improves fleet utilization and spreads compliance and handling costs across recurring deliveries, supporting the current dominance of scheduled transportation.

Time-critical / just-in-time transportation is gaining share at the fastest pace as more customers require expedited dispatch, recovery movements and delivery commitments that cannot be absorbed within standard route cycles. For instance, Marken offers distinct same-day, next-flight-out and white-glove final-mile services for radiopharmaceutical and nuclear-medicine shipments across more than 220 countries and territories, demonstrating the commercialization of dedicated urgent-service tiers. These movements typically require immediate carrier access, reserved operational capacity and higher-touch coordination, reducing opportunities for route consolidation and increasing service costs. The shift raises the value of providers with documented response times, broad urgent-delivery coverage and the capacity to accept unplanned or recovery shipments without disrupting scheduled operations.

Which Type of Radiopharmaceuticals Dominate the Global Logistics Market?

Diagnostic radiopharmaceutical logistics dominate the current global market, supported by the recurring use of PET and SPECT products across oncology, cardiology, neurology and other imaging pathways. Curium reports that its diagnostic portfolio serves approximately 14 million patients annually through a vertically integrated manufacturing and distribution network, illustrating the scale of repeat dose preparation and delivery generated by established nuclear-medicine practice. This broad utilization creates dense, recurring logistics flows across radiopharmacies, imaging centres and hospitals, making diagnostic products the largest current revenue base for transport, dispensing coordination and final delivery.

Therapeutic radiopharmaceutical logistics is projected to expand most rapidly as commercial and clinical programs broaden across beta- and alpha-emitting radionuclides. Cardinal Health quadrupled its weekly Ac-225 output after establishing routine production, while Curium announced a new European production line for Lu-177 PSMA therapy in June 2026. These investments indicate a widening therapeutic payload mix and more frequent movement of isotopes, intermediates and finished doses through specialized networks. The logistics opportunity arises from the greater service intensity associated with controlled release, isotope-specific handling, documentation and treatment-site supply, rather than from assuming that therapeutic product growth translates mechanically into logistics revenue.

Temperature Range Market Analysis: Ambient / Controlled Room Temperature Leads, While Ultra-Low Temperature / Cryogenic Logistics are Projected to Grow Fastest

Ambient / controlled room temperature logistics hold the largest market share of 52.0% in the current year, as a broad range of diagnostic and therapeutic radiopharmaceuticals can be transported within validated room-temperature conditions. Fludeoxyglucose F 18 Injection is stored at controlled room temperature, while the LUTATHERA (targeted radiopharmaceutical, developed by Novartis) label specifies storage below 25°C and prohibits freezing. The applicability of these conditions across widely distributed products creates a large shipment base that can be served through qualified ambient packaging and monitoring systems. Although radiation shielding, timing and chain-of-custody controls remain essential, the limited need for active refrigerated or frozen infrastructure supports the segment's current leadership.

Ultra-low temperature / cryogenic logistics segment is projected to register a higher CAGR till 2035. This faster pace is driven by the widening pipeline of complex therapeutics, investigational materials and specialized radiopharmaceutical products that require more tightly controlled storage, qualified thermal packaging and intensive excursion management. NorthStar's current radiopharmaceutical CDMO platform supports Phase I-III clinical manufacturing, dedicated logistics operations and Type A shipping with cold-chain capabilities, demonstrating how temperature-control requirements are being incorporated earlier into emerging product supply chains. As these programs progress, demand will rise for multitemperature qualification, calibrated monitoring and specialist handling, widening the capability gap between general radiopharmaceutical carriers and providers equipped to manage the most demanding temperature bands.

Market Dynamics

What are the Key Factors Which Drive Radiopharmaceutical Logistics Industry Growth?

• Increased Inclination Toward Specialist Logistics Outsourcing: Manufacturers increasingly rely on external partners to perform regulated distribution activities that would be costly to replicate across every market. GE HealthCare's distribution and services agreement with CardioNavix, for instance, uses an established network to support Flyrcado availability across hospital and outpatient settings, showing how commercial distribution and operational support can be contracted externally. Where such agreements include Class 7 transportation, qualified packaging, documentation, monitoring, chain-of-custody control or radiopharmacy delivery, they increase third-party market penetration. This supports scalable commercialization while increasing demand for providers with integrated compliance and distribution capabilities.
• Growth in Nuclear-Medicine Capacity: The Society of Nuclear Medicine and Molecular Imaging (SNMMI) reported in November 2025 that rising radiopharmaceutical-therapy demand could require hundreds of thousands of treatment cycles and hundreds of additional treatment centres worldwide. As new nuclear-medicine, PET and therapy sites become operational, each location creates repeat requirements for dose ordering, shipment preparation and delivery aligned with procedure throughput. Higher utilization at existing sites further increases recurring shipment activity. The resulting service opportunity depends on confirmed site activation and sustained clinical volumes, requiring logistics providers to align route capacity and delivery coverage with actual demand rather than announced infrastructure plans alone.

What are the Challenges Limiting the Growth of the Radioactive Drug Product Logistics Market?

• Class 7, Customs and Carrier Requirements Constrain Cross-Border Logistics Scalability: Radiopharmaceutical shipments are transported as Class 7 radioactive materials and must meet applicable requirements for package classification, marking, labelling, shipment documentation and carrier acceptance before they can move through domestic or international transport networks. Cross-border movements add customs procedures, competent-authority notifications or approvals and country-specific requirements to this compliance burden. The IAEA's 2025 regulations establish the international framework for radioactive-material transport, while IATA's 2026 radioactive-shipment checklist requires applicable acceptance criteria to be verified before an air shipment is accepted. Documentation gaps, approval delays or carrier restrictions can therefore postpone shipment release or make otherwise viable routes unavailable, increasing specialist staffing and lane-qualification costs while limiting the number of routes that logistics providers can scale internationally.
• Treatment-Site Readiness and Reimbursement Gaps: Radiopharmaceutical availability does not translate into shipment demand until receiving sites have the required clinical infrastructure, authorized personnel and reimbursement support. SNMMI requirements show that therapy sites need authorized users, certified technologists and suitable clinical capabilities, with advanced centres requiring additional imaging, safety and multidisciplinary resources. Reimbursement can also affect utilization. In the US, CMS introduced a USD 10 add-on payment from January 2026 for eligible technetium-99m doses produced from domestically sourced molybdenum-99 to address higher supply costs. These dependencies can delay site activation and increase the risk of committing logistics capacity before sustainable throughput is established.

Future Innovation and Market Opportunity: Predictive Analytics and Digital Twin Modelling Are Advancing Radiopharmaceutical Logistics Planning

The use of predictive analytics and digital twins in healthcare supply chain is improving radiopharmaceutical logistics planning by allowing providers to test operational scenarios before dispatching. In March 2026, World Courier identified digital twins as relevant to highly regulated radiopharmaceutical supply chains because virtual network models can test assumptions and anticipate disruption before a shipment moves. Applied operationally, these tools could model authorization lead times, carrier restrictions, packaging endurance, alternative lanes, disruption exposure and capacity requirements. The capability is not yet established as a market-wide standard, but it could differentiate providers through predictive route qualification, risk-adjusted capacity reservation and stronger contingency economics. Technology suppliers may participate through platforms embedded within externally billed logistics services.

Recent Developments in the Radiopharmaceutical Logistics Market

• June 2026: Curium announced an investment of more than EUR 32 million to establish a production line for lutetium-177 PSMA-I&T at Saclay, France, serving anticipated European demand. The investment may increase movements of isotope inputs and finished therapeutic products requiring qualified regional distribution, although manufacturing value remains outside the logistics-market denominator.
• April 2026: Cardinal Health expanded actinium-225 production at its Indianapolis Center for Theranostics Advancement after quadrupling weekly output since beginning routine scaled production in late 2024. Higher isotope availability can support additional investigational and future commercial drug-product flows, increasing requirements for compliant handling and distribution without classifying isotope-production revenue as logistics revenue.
• March 2026: The IAEA published the 2025 edition of its Regulations for the Safe Transport of Radioactive Material. The revised international framework applies across transport modes and affects package classification, documentation, approvals and implementation requirements used to qualify radioactive-material routes, including applicable radiopharmaceutical shipments.
• January 2026: SHINE completed its acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts manufacturing facility and diagnostic radiopharmaceutical portfolio. The transaction strengthens SHINE's position across isotope supply and radiopharmaceutical operations and may influence supply continuity, distribution arrangements and the role of external logistics partners.

Radiopharmaceutical Logistics Maret Report Coverage

Research Scope and Methodology

The study examines externally provided logistics services supporting medical radiopharmaceuticals and medical isotopes, including transportation, storage, packaging, monitoring, documentation and specialized handling. The analysis uses the proprietary Roots Analysis research framework, supported by proprietary databases repositories, company disclosures, regulatory publications, product information, industry literature and secondary sources. Market estimates and forecasts were tested against company activity, infrastructure development, commercialization trends, outsourcing patterns and operational and regulatory risks. For further details, see the complete research methodology adopted by Roots Analysis across its market reports.

Business Intelligence for Strategic Decision-Making in the Radiopharmaceutical Logistics Market

• Market & Growth Intelligence: The report provides annual market estimates from 2022 to 2035 and evaluates growth across service type, radiopharmaceutical type, radioisotope half-life, temperature range, end user and region. It also examines transportation mode and delivery type within Transportation and Courier Services, while preserving the applicable parent-level denominators. This structure enables comparison of current revenue concentration, faster-growing service requirements and regional expansion patterns. The analysis supports decisions related to capacity allocation, service-portfolio development, geographic prioritization and the timing of investment in specialist logistics capabilities.
• Competitive Landscape & Company Insights: Competitive analysis distinguishes specialist logistics providers, integrated healthcare-logistics groups, radiopharmacy networks and manufacturer-led distribution systems according to their operating roles. Companies are assessed across delivery infrastructure, radiopharmaceutical portfolios handled, compliance capabilities, technology use and geographic reach. The report also examines partnerships, radiopharmacy expansion, distribution agreements and outsourcing relationships that influence market access and service coverage. These insights support provider benchmarking, partner selection, competitive-positioning assessment and evaluation of whether market entry requires direct infrastructure, regional alliances or access to established licensed networks.
• Technology & Innovation Insights: The report evaluates how shipment visibility, condition monitoring, chain-of-custody systems, qualified packaging and predictive planning capabilities are influencing radiopharmaceutical logistics services. It distinguishes established operational tools from emerging applications such as digital-twin modelling, route simulation and risk-adjusted capacity planning. Technology developments are assessed according to their ability to improve compliance, pre-shipment planning, intervention readiness and service differentiation rather than as standalone software opportunities. The analysis enables comparison of provider readiness across multiple validated temperature bands, transport conditions and increasingly complex regulatory and operational requirements.
• Strategic Business Intelligence: The report integrates market forecasts with regulatory, operational and commercialization considerations that determine whether logistics demand can be realized. It examines Class 7 requirements, customs and carrier acceptance, treatment-site readiness, reimbursement conditions, outsourced-versus-captive execution and the allocation of revenue within integrated service contracts. It also considers how clinical-site activation, therapeutic commercialization and specialist outsourcing affect shipment activity and third-party market penetration. This combined view supports route-feasibility assessment, supplier due diligence, contract design, regional expansion planning and evaluation of the infrastructure required to serve diagnostic and therapeutic radiopharmaceutical programs.

Radiopharmaceutical Logistics Maret: Report Attributes